8-K: Helius Medical Technologies Shareholders Approve Reverse Stock Split and Major Equity Financing Plan

Helius Medical Technologies, Inc. announced that its stockholders approved a reverse stock split, an increase in authorized shares, and the issuance of shares for a potential financing at a special meeting on May 23, 2025.

Summary

• At a special meeting held on May 23, 2025, Helius Medical Technologies, Inc. stockholders approved five key proposals.
• Proposal 1, the Reverse Stock Split, allowing for a ratio of 1-to-2 to 1-to-250 at the Board's discretion to comply with Nasdaq listing requirements, was approved with 4,126,134 votes for, 262,889 against, and 6,797 abstentions.
• Proposal 2, increasing the number of authorized common stock shares to up to 800,000,000, received approval with 4,204,034 votes for, 154,412 against, and 37,374 abstentions.
• Proposal 3, the issuance of up to 148,621,326 shares of common stock in a potential financing, was approved with 2,434,917 votes for, 113,603 against, and 19,031 abstentions, alongside 1,828,269 broker non-votes.
• Proposal 4, an amendment to the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan, was approved with 2,382,565 votes for, 148,780 against, and 36,206 abstentions, with 1,828,269 broker non-votes.
• Proposal 5, authorizing one or more adjournments of the Special Meeting to solicit additional proxies if needed for Proposals 1, 2, 3, or 4, was approved with 4,195,183 votes for, 155,972 against, and 44,665 abstentions.
• All reported voting numbers are based on outstanding shares as of the April 25, 2025 record date and have not been adjusted to reflect the reverse stock split effected on May 2, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive because all critical proposals were approved, addressing immediate compliance and funding needs. However, the underlying reasons for these actions (Nasdaq compliance issues, need for significant financing) indicate ongoing challenges and potential future dilution, preventing a higher score.

Positives

• Shareholder approval of the reverse stock split is crucial for the company to maintain compliance with Nasdaq's continued listing requirements, mitigating the risk of delisting.
• The approval to increase authorized shares provides Helius Medical Technologies with significant flexibility for future capital raises or strategic corporate transactions.
• The authorization for the issuance of up to 148,621,326 shares for a potential financing indicates a clear path for the company to secure necessary capital for ongoing operations and future growth initiatives.
• The amendment to the 2022 Equity Incentive Plan can enhance the company's ability to attract, retain, and incentivize key talent through equity compensation.

Negatives

• The necessity for a reverse stock split implies that the company's stock price has fallen below Nasdaq's minimum bid price requirement, signaling past or ongoing underperformance.
• The potential financing, while vital for capital, could lead to substantial dilution for existing shareholders given the large number of shares (up to 148,621,326) authorized for issuance.

Risks

• Risk of delisting from Nasdaq if the reverse stock split, despite approval, does not effectively enable the company to maintain compliance with listing requirements.
• Significant potential for shareholder dilution due to the authorized issuance of up to 148,621,326 shares in a future financing, which could negatively impact per-share value.
• The company's need for both a reverse stock split and substantial additional financing suggests underlying financial challenges or a significant capital requirement for its business model.

Future Outlook

Helius Medical Technologies has successfully secured shareholder approval for critical corporate actions, including a reverse stock split to address Nasdaq listing compliance and the authorization for a substantial equity financing. This positions the company to resolve immediate regulatory concerns and pursue future capital raises, although the specific terms and timing of the financing, and its ultimate impact on the company's financial structure, remain to be determined.

Management Comments

• The numbers reported are based on outstanding shares of the Company’s Common Stock as of April 25, 2025, the record date of the Special Meeting, and, as such, have not been adjusted to reflect the reverse stock split of the Company’s Common Stock effected on May 2, 2025.

Industry Context

In the medical technology sector, particularly for smaller or development-stage companies, maintaining stock exchange listing requirements and securing adequate capital for research, development, and commercialization are persistent challenges. Reverse stock splits are a common mechanism employed by companies to boost their share price to meet minimum bid requirements, while equity financings are crucial for funding operations, clinical trials, and market expansion. This filing reflects typical corporate actions taken by companies in this industry to ensure operational continuity and access to capital markets.

Comparison to Industry Standards

• Reverse stock splits are a common strategy for companies, particularly in the biotech and medtech sectors, that fall below exchange minimum bid price requirements. Companies such as *Sorrento Therapeutics* or *Cassava Sciences* have similarly undertaken reverse splits to maintain Nasdaq compliance.
• The authorization of a large number of shares for potential financing is typical for growth-stage companies in the medical device industry that require substantial capital for clinical trials, regulatory approvals, and market penetration. For instance, *Inovio Pharmaceuticals* or *Athersys* have frequently sought shareholder approval for increased authorized shares to facilitate future capital raises.
• The broad range for the reverse split ratio (1-to-2 to 1-to-250) provides the Board with significant discretion, which is not uncommon but can introduce uncertainty regarding the final share structure compared to a fixed ratio.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Will experience a reverse stock split, which will reduce the number of shares they own but increase the per-share price. They also face potential significant dilution from the approved share issuance for future financing.
• **Employees**: The amendment to the Equity Incentive Plan could benefit employees through increased stock-based compensation opportunities, enhancing retention and motivation.
• **Creditors**: A successful future financing, enabled by these approvals, could improve the company's financial stability and liquidity, potentially reducing credit risk.

Next Steps

• The Board of Directors will determine the exact ratio for the reverse stock split within the approved range (1-to-2 to 1-to-250).
• The company is now authorized to proceed with a potential financing, leveraging the approved authorization to issue up to 148,621,326 shares.
• The company will continue its efforts to comply with Nasdaq's continued listing requirements following the reverse stock split.

Key Dates

Keywords

Helius Medical Technologies, HSDT, SEC filing, 8-K, reverse stock split, Nasdaq compliance, authorized shares, equity financing, stock issuance, shareholder meeting, corporate governance, equity incentive plan, medical technology